Ascentage Pharma Group International
AAPG24.520USD
+0.330+1.36%
終値 02/06, 16:00（ET）15分遅れの株価
0.00時価総額
--直近12ヶ月PER
詳細情報 Ascentage Pharma Group International 企業名
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
Ascentage Pharma Group Internationalの企業情報
企業コードAAPG
会社名Ascentage Pharma Group International
上場日Oct 28, 2019
最高経営責任者「CEO」Yang (Dajun)
従業員数- -
証券種類Depository Receipt
決算期末- -
本社所在地68 Xinqing Road, Suzhou Industrial Park
都市SUZHOU
証券取引所NASDAQ OMX - NASDAQ BASIC
国China
郵便番号- -
電話番号
ウェブサイトhttps://www.ascentage.cn/
企業コードAAPG
上場日Oct 28, 2019
最高経営責任者「CEO」Yang (Dajun)
Ascentage Pharma Group Internationalの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Non-Executive Director
Independent Non-Executive Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Tue, Jan 20
更新時刻: Tue, Jan 20
株主統計
種類
株主統計
株主統計
比率
XY Capital Ltd.
0.02%
Point72 (DIFC) Ltd
0.02%
NEOS Investment Management, LLC
0.01%
Citadel Advisors LLC
0.01%
他の
99.94%
株主統計
株主統計
比率
XY Capital Ltd.
0.02%
Point72 (DIFC) Ltd
0.02%
NEOS Investment Management, LLC
0.01%
Citadel Advisors LLC
0.01%
他の
99.94%
種類
株主統計
比率
Investment Advisor
0.06%
Hedge Fund
0.01%
他の
99.93%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
23
89.21K
0.29%
--
2025Q3
23
89.21K
0.29%
+6.09K
2025Q2
16
82.77K
0.27%
-154.43K
2025Q1
6
237.19K
0.00%
+237.19K
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
XY Capital Ltd.
18.12K
0.02%
+12.53K
+224.15%
Sep 30, 2025
Point72 (DIFC) Ltd
17.93K
0.02%
-2.96K
-14.17%
Sep 30, 2025
NEOS Investment Management, LLC
10.38K
0.01%
-5.11K
-32.98%
Sep 30, 2025
Citadel Advisors LLC
9.65K
0.01%
+9.65K
--
Sep 30, 2025
UBS Financial Services, Inc.
18.34K
0.02%
+10.99K
+149.35%
Sep 30, 2025
Mirae Asset Global Investments (USA) LLC
2.46K
0%
+2.46K
--
Sep 30, 2025
Tower Research Capital LLC
829.00
0%
+829.00
--
Sep 30, 2025
Geode Capital Management, L.L.C.
361.00
0%
--
--
Nov 30, 2025
Osaic Holdings, Inc.
220.00
0%
+220.00
--
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Tema Oncology ETF
0.43%
Invesco Golden Dragon China ETF
0%
Tema Oncology ETF
比率0.43%
Invesco Golden Dragon China ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
